Rachel McSwain
Primary Care · Olgethorpe, GANPI 1952795098
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 166 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 18 manufacturers reported payments, led by GSK at 27.8% of the total. Reporting peaked in 2021 at $1,009 and has fallen 64.1% since, to $362 in 2025.
Across 166 payments — averaging $16.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$774
- Novo Nordisk$467
- AstraZeneca$358
- Lilly USA, LLC$341
- Boehringer Ingelheim$222
- Novartis$118
- plus $500 from 12 others
What the payments were for
- Food & beverage$2,781100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 47 | $774 |
| Novo Nordisk | 26 | $467 |
| AstraZeneca | 25 | $358 |
| Lilly USA, LLC | 21 | $341 |
| Boehringer Ingelheim | 12 | $222 |
| Novartis | 7 | $118 |
| Esperion Therapeutics, Inc. | 7 | $111 |
| Otsuka America Pharmaceutical, Inc. | 4 | $76 |
| Sanofi-aventis U.S. LLC | 4 | $66 |
| Exact Sciences | 3 | $55 |
| Amgen | 3 | $50 |
| Biohaven Pharmaceuticals, Inc. | 1 | $28 |
| AbbVie | 1 | $24 |
| Aytu Biopharma, Inc. | 1 | $22 |
| Dexcom, Inc. | 1 | $21 |
| Biogen | 1 | $18 |
| Merck | 1 | $16 |
| E.r. Squibb & Sons, L.L.C. | 1 | $12 |
How this compares
$2,781 in reported general payments places this provider in the 80th percentile of 235 primary care providers in Georgia.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 81 | $105,193 |
| RybelsusSemaglutide | 26 | $52,081 |
| FarxigaDapagliflozin Propanediol | 44 | $48,106 |
| LinzessLinaclotide | 37 | $34,145 |
| OzempicSemaglutide | 16 | $26,238 |
| TradjentaLinagliptin | 12 | $18,595 |
| MounjaroTirzepatide | 16 | $16,290 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 17 | $15,780 |
| JanuviaSitagliptin Phosphate | 14 | $14,765 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 13 | $14,542 |
| EliquisApixaban | 13 | $9,116 |
| Atorvastatin Calcium | 268 | $1,809 |
| Gabapentin | 76 | $1,366 |
| Losartan Potassium | 116 | $1,242 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 11 | $1,222 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Tradjenta | $222 | $123,78993 claims |
| Novo NordiskRybelsus, Ozempic | $467 | $78,31942 claims |
| AstraZenecaFarxiga | $358 | $48,10644 claims |
| AbbVieLinzess | $24 | $34,14537 claims |
| Lilly USA, LLCMounjaro | $341 | $16,29016 claims |
| GSKAnoro Ellipta | $774 | $15,78017 claims |
| MerckJanuvia | $16 | $14,76514 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $66 | $14,54213 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 235 primary care providers in Georgia.
Other primary care in Olgethorpe
- Pamela TurkDouglas$15K
- Morgan JonesLawrenceville$14K
- Jessi HaleColumbus$13K
- Meredith CarrAugusta$12K
- Ashtyn ZaryckiSavannah$12K
- Zanetta BryantNewnan$11K
- Hannah CummingsSuwanee$9K
- Michelle LadewigGainesville$7K
- Lucia OcanoviciuCanton$7K
- Sarah NewGrovetown$7K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.